Skip to main content
Figure 1 | Allergy, Asthma & Clinical Immunology

Figure 1

From: Add-on histamine receptor-3 antagonist for allergic rhinitis: a double blind randomized crossover trial using the environmental exposure unit

Figure 1

Time-course of change in symptom scores post-treatment. Exploratory visualization of the change in symptom scores (Δ to baseline) are shown for A) Congestion, and B) Total Nasal Symptom Score (TNSS) from time of drug administration (0 hours) to 6 hours post-treatment. Lines and error bars represent the raw means and standard errors of the means for each of the treatments over time. It includes all participant study periods in which a participant was administered a treatment and remained in the EEU for the entire study period (excludes those periods where a participant discontinued the study without completing the visit). The y-intercept represents baseline, defined as the mean of the last two pre-treatment symptom scores (-0.5H and 0H). Samples sizes were; n = 86, 96, 28 and 14 for PF-03654764 + fexofenadine, fexofenadine + pseudoephedrine, PF-03654764, and placebo, respectively.

Back to article page